German biopharmaceutical company CureVac (NASDAQ:CVAC) has said its potential vaccine against COVID-19, known as CVnCoV, induced an immune response in pre-clinical animal studies, Reuters news agency reported on Friday.
According to CureVac, CVnCoV produced neutralising antibodies and activated T-cells in hamsters and mice.
The new vaccine, which is being tested in humans in early and mid-stage trials, also protected the lungs of hamsters when they were exposed to a live virus, the company said.
CureVac chief technology officer Mariola Fotin-Mleczek was quoted as saying: "The pre-clinical data published today show that our COVID-19 vaccine candidate has the potential to induce an efficacious and balanced immune response, mimicking the natural immune defence and providing lung protection in a relevant challenge model."
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV